Dual vector and AAV.SPR technologies combine to drive supraphysiological levels of full-length MYO7A in non-human primate retina, reaching the macula without foveal detachment Six-month GLP … The post Atsena Therapeutics Reports New Preclinical Data Demonstrating Robust MYO7A Expression and Favorable Safety for ATSN-301, a Laterally Spreading Dual AAV Vector-based Gene Therapy for Usher Syndrome Type 1B appeared first on Atsena Therapeutics .